Premium
Drug holiday approach for Vismodegib treatment in patients with nevoid basal cell carcinoma syndrome: Three cases from real clinical practice
Author(s) -
ValenzuelaOñate Cristian Alejandro,
MagdalenoTapial Jorge,
GarciaLegaz Martínez Marta,
PerezPastor Gemma,
Sanchez Carazo José Luis
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13540
Subject(s) - vismodegib , medicine , nevoid basal cell carcinoma syndrome , basal cell carcinoma , drug , adverse effect , basal (medicine) , dermatology , drug holiday , oncology , basal cell , pharmacology , immunology , human immunodeficiency virus (hiv) , insulin
Sonic hedgehog pathway inhibitor Vismodegib is the first systemic treatment to be approved for metastatic or locally advanced basal cell carcinoma non‐subsidiary of surgical treatment, and appears to be a promising treatment option for patients with nevoid basal cell carcinoma syndrome. In these patients, where repeated or prolonged treatment may be necessary, the psychological exhaustion caused by the chronicity of less severe adverse effects appears as the main limiting factor in the persistence of the drug in the long term and in the willingness of patients to take the drug again after its suspension. We report our experience with three cases where a drug holiday approach was effective in decreasing the intensity of adverse effects or improving the patient's subjective tolerance to the drug while maintaining clinical response.